Treatment of hepatocellular carcinoma: A summary of 33 years’ experience

Tang, Zhao–You; Yu, Yu; Zhou, Xin‐Da; Yang, Benlong; Lu, Jianwei; Ma, Zeng‐Chen; Ye, Sheng‐Long; Liu, Kang‐Da; Zhuyuan, YU

doi:10.1007/978-4-431-68177-9_44

Cited by 5 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After treating 41 patients with unresectable HCC with 131I-coupled anti-ferritin antibody, 13 patients underwent "second stage" resection. The 3-year survival of the whole group (including the no-resection patients) was 26% [19]. In a similar study 34 patients were treated with intraarterial a31I-Lipiodol.…”

Section: Cirrhosismentioning

confidence: 84%

“…In a similar study 34 patients were treated with intraarterial a31I-Lipiodol. Eleven patients underwent second stage resection, and the 3-year survival was 55% [19]. Following treatment with a combination of external radiotherapy, chemotherapy, and radiolabeled anti-ferritin antibody, partial tumor regression was observed in 14 patients with HCC initially deemed unresectable.…”

Section: Cirrhosismentioning

confidence: 99%

“…Adjuvant 5-FU (600-800 mg/day) administered orally did not prevent recurrence following curative resection of HCC [24]. Adjuvant hepatic artery infusion With Survival (%) Tang ~ [27] 18/37 18 ------36 Lange [28] 11 ------28 Tang ~ [19] 66 --41 30 --Nagao [29] 8/41 8 --50 ----Suenaga [10] "These studies included patients with pulmonary or mediastinal recurrence treated by reresection. 5-FU, mitomycin C, and doxorubicin has been used in 19 patients followed for up to 18 months.…”

Section: Cirrhosismentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic modalities and prognostic factors for primary and secondary liver tumors

1995

View full text Add to dashboard Cite

During the past decade considerable progress has been reported in the treatment of primary and secondary hepatic malignancies. Refined techniques in surgery, transplantation, radiotherapy, and chemotherapy apparently have made the delivery of treatment safer. At the same time improved understanding of tumor biology has been incorporated in treatment strategies. More recently specific and nonspecific, active and passive immunotherapies have excited wide interest, and information from the first randomized studies is now available. We review current treatment options for primary and secondary hepatic malignancies in an attempt to extract plausible treatment guidelines and to identify promising future directions.

show abstract

Section: Cirrhosismentioning

confidence: 84%

Section: Cirrhosismentioning

confidence: 99%

Section: Cirrhosismentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic modalities and prognostic factors for primary and secondary liver tumors

1995

View full text Add to dashboard Cite

show abstract

“…In this series, 13 of the 68 SCHCC patients who had palliative surgery received sequential resection; the 5-year survival increased up to 20.496, which was rarely encountered in patients with unresectable HCC. In the authors' institute, the 5-year survival of 34 patients with unresectable HCC receiving cytoreduction and sequential resection was as high as 62.0% [18].…”

Section: Resultsmentioning

confidence: 99%

Subclinical hepatocellular carcinoma: An analysis of 391 patients

Tang

Zhou

et al. 1993

J. Surg. Oncol.

Self Cite

View full text Add to dashboard Cite

Subclinical hepatocellular carcinoma (SCHCC) is defined as HCC without obvious HCC symptoms and signs. During 1958During -1991 patients with SCHCC were analyzed. In the entire series, 1) 67.3% was detected by natural population screening using alpha-fetoprotein (AFP) serosurvey , while the others were discovered by high-risk population screening or regular health checkup using AFP and/or ultrasonography (US); 2) AFP > 20 pg/L was found in 77.6% of patients; 3) serum hepatitis B surface antigen (HBsAg) was positive in 68.9%; 4) associated liver cirrhosis occurred in 89.1%; 5) the median tumor size was 5 cm, and small HCC ( S 5 cm) amounted to 61.1%; 6) resection was done in 8 1.4%, and limited resection was performed in the majority (71.3%); 7) re-resection for subclinical recurrence was done in 44 patients; and 8) cytoreduction and sequential resection was carried out in 13 patients with unresectable SCHCC. Comparison between SCHCC and clinical HCC (n = 1,251) revealed higher resectability (81.4% vs. 46.8%), lower operative mortality (1.9% vs. 6.0%), and higher 5-year survival (entire series: 50.7% vs. 20.6%; resection: 60.5% vs. 36.8%). It is concluded that the study of SCHCC has resulted in marked improvement of ultimate outcome of HCC; screening in high-risk populations using AFP and/or US, limited resection, and re-resection for subclinical recurrence are some of the key features.

show abstract

“…This occurred in 10% of our patients, and a rate of secondary resectability after TACE as high as 33% has been reported in a Chinese study. 35 The incentive for secondary resection in our (Fig. 8).…”

Section: Resectionmentioning

confidence: 99%

Influence of Preoperative Transarterial Lipiodol Chemoembolization on Resection and Transplantation for Hepatocellular Carcinoma in Patients With Cirrhosis

Majno

Adam²,

Bismuth³

et al. 1997

Annals of Surgery

479

371

View full text Add to dashboard Cite

ObjectiveTo investigate the impact of preoperative transarterial lipiodol chemoembolization (TACE) in the management of patients undergoing liver resection or liver transplantation for hepatocellular carcinoma. Patients and MethodsTACE was performed before surgery in 49 of 76 patients undergoing resection and in 54 of 111 patients undergoing liver transplantation. Results were retrospectively analyzed with regard to the response to treatment, the type of procedure performed, the incidence of complications, the incidence and pattern of recurrence, and survival. ResultsIn liver resection, downstaging of the tumor by TACE (21 of ConclusionsDownstaging or total necrosis of the tumor induced by TACE occurred in 62% of the cases and was associated with improved disease-free survival both after liver resection and 688

show abstract

Treatment of hepatocellular carcinoma: A summary of 33 years’ experience

Cited by 5 publications

References 11 publications

Therapeutic modalities and prognostic factors for primary and secondary liver tumors

Therapeutic modalities and prognostic factors for primary and secondary liver tumors

Subclinical hepatocellular carcinoma: An analysis of 391 patients

Influence of Preoperative Transarterial Lipiodol Chemoembolization on Resection and Transplantation for Hepatocellular Carcinoma in Patients With Cirrhosis

Contact Info

Product

Resources

About